The future of b-cell lymphoma therapy: The B-cell receptor and its downstream pathways

Current Hematologic Malignancy Reports

Volumn 7, Issue 3, 2012, Pages 216-220

  Kenkre, Vaishalee P ^a,b,c   Kahl, Brad S ^a,b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

B cell receptor; Bruton's tyrosine kinase (BTK); Non Hodgkin lymphoma; Phosphoinositide 3 kinase (PI3K); Spleen tyrosine kinase (Syk); Targeted therapy

Indexed keywords

5 FLUORO 3 PHENYL 2 [1 (9H PURIN 6 YLAMINO)PROPYL] 3H QUINAZOLIN 4 ONE; B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; FOSTAMATINIB; IBRUTINIB; NUCLEOSIDE ANALOG; PHOSPHATIDYLINOSITOL 3 KINASE; PICEATANNOL; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANOREXIA; ASTHENIA; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; ENZYME PHOSPHORYLATION; FATIGUE; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; HUMAN; HYPERTENSION; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PNEUMONIA; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT DURATION; UPPER ABDOMINAL PAIN; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC AGENTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOMA, B-CELL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 84865973672     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0127-0     Document Type: Review

References (22)

1. Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004;117:787-800.
2. Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 1997;90:1073-83.
3. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010; 362:1417-29.
4. Gururajan M, Jennings CD, Bondada S. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol. 2006;176:5715-9.
5. Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large Bcell lymphoma. Blood. 2008;111:2230-7.
6. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105:1851-61.
7. Chen L, Juszczynski P, Takeyama K, Aguiar RC, Shipp MA. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood. 2006;108:3428-33.
8. Irish JM, Czerwinski DK, Nolan GP, Levy R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood. 2006;108:3135-42.
9. Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006;132:303-16.
10. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. ;115:2578-85. This is the first publication revealing the promise of BCR targeting in B cell lymphomas.
11. Satterthwaite AB, Witte O. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000;175:120-7.
12. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075-80.
13. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287-96.
14. Advani A, Sharman J, Smith SM. The Btk inhibitor PCI-32765 is highly active and well tolerated in patients with relapsed/refractory B cell malignancies: final results from a phase I study. Ann Oncol. 2011;22 (Suppl 4).
15. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88-92.
16. O'Brien S Burger JA, Blum KA, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Follow up of a phase IB/II study. Blood. 2011; 118: Abstract 983. This abstract details the phase II experience with PCI 32765 in CLL.
17. Wang L, Martin P, Blum KA, et al. The Bruton's Tyrosine Kinase Inhibitor PCI-32765 is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. Blood. 2011;118: Abstract 442. This abstract details the phase II experience with PCI 32765 in MCL.
18. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117:591-4.
19. Furman RR, Byrd JC, Brown JR et al. CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood. 2010; 116: Abstract 55. This abstract details the phase I experience with CAL 101 in CLL.
20. Kahl BS, Byrd JC, Flinn IW, et al. Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Blood. 2010; 116: Abstract 1777. This abstract details the phase I experience with CAL 101 in NHL.
21. De Vos S, MT S, IW F. A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies. Blood. ;118:Abstract 2699.
22. Sharman J, de Vos S, Leonard JP. A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K{delta}) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Blood 2011;118:Abstract 1787.